Department: Clinical Trial Operations, International Operations
Location: Vicente López, Buenos Aires. Hybrid working.
As Study Start Up Analyst, you will help clinical trials in Argentina get started on time and the right way. You will prepare and submit the documents that Health Authorities and Ethics Committees need to approve a trial. When your work is accurate and fast, sites can start sooner. That keeps research moving for people living with serious chronic diseases.
You will own start-up and submission activities for your assigned trials, from the first plan to green light – the final approval for a site to start.
You will join Clinical Trial Operations team and report to Adriana Demes, Trial Start-Up Manager. Every day, you will work with Trial Managers and local trial teams.
You will also build strong relationships with trial sites, Ethics Committees, Health Authorities and vendors. Good teamwork here keeps trials on track.
You will own important work from the start, and your ideas will be heard. You will learn from experts in clinical, regulatory and quality, and build skills that help you grow. We move fast, support each other and never compromise on patient safety or quality.
Your impact begins today. Apply for the Study Start Up Analyst role by 10 October 2026.
Novo Nordisk is an equal opportunity employer. We welcome applications from all qualified candidates. Every application is considered without regard to gender, gender identity, sexual orientation, age, ethnicity, nationality, religion, disability, marital status or any other characteristic protected by law. If you need adjustments during the recruitment process, let us know.

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health.
Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com.
This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.
Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in:
https://www.novonordisk.com/contact-us/find-local-information.html
For other customer complaints, please contact us here:
https://www.novonordisk.com/contact-us.html
Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed.
Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users.
Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html